Intellectual Capital and the Birth of US Biotechnology Enterprises

Working Paper: NBER ID: w4653

Authors: Lynne G. Zucker; Michael R. Darby; Marilynn B. Brewer

Abstract: We examine the relationship between the intellectual capital of scientists making frontier discoveries, the presence of great university bioscience programs, the presence of venture capital firms, other economic variables, and the founding of U.S. biotechnology enterprises during 1976-1989. Using a linked cross-section/time- series panel data set, we find that the timing and location of the birth of biotech enterprises is determined primarily by intellectual capital measures, particularly the local number of highly productive 'star' scientists actively publishing genetic sequence discoveries. Great universities are likely to grow and recruit star scientists, but their effect is separable from the universities. When the intellectual capital measures are included in our poisson regressions, the number of venture capital firms in an area reduces the probability of foundings. At least early in the process, star scientists appear to be the scarce, immobile factors of production. Our focus on intellectual capital is related to knowledge spillovers, but in this case 'natural excludability' permits capture of supranormal returns by scientists. Given this reward structure technology transfer was vigorous without any special intermediating structures. We believe biotechnology may be prototypical of the birth patterns in other innovative industries.

Keywords: Intellectual Capital; Biotechnology; Venture Capital; Firm Formation

JEL Codes: O31; L26


Causal Claims Network Graph

Edges that are evidenced by causal inference methods are in orange, and the rest are in light blue.


Causal Claims

CauseEffect
intellectual capital (O34)founding of biotech enterprises (L65)
local number of star scientists actively publishing genetic sequence discoveries (C59)founding of biotech enterprises (L65)
presence of universities (I23)founding of biotech enterprises (L65)
presence of venture capital firms (G24)founding of biotech enterprises (L65)

Back to index